210 related articles for article (PubMed ID: 23857707)
1. Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study.
Grill J; Geoerger B; Gesner L; Perek D; Leblond P; Cañete A; Aerts I; Madero L; de Toledo Codina JS; Verlooy J; Estlin E; Cisar L; Breazna A; Dorman A; Bailey S; Nicolin G; Grundy RG; Hargrave D;
Neuro Oncol; 2013 Sep; 15(9):1236-43. PubMed ID: 23857707
[TBL] [Abstract][Full Text] [Related]
2. A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.
Hargrave D; Geoerger B; Frappaz D; Pietsch T; Gesner L; Cisar L; Breazna A; Dorman A; Cruz-Martinez O; Fuster JL; Rialland X; Icher C; Leblond P; Ashley D; Perilongo G; Elliott M; English M; Clausen N; Grill J
J Neurooncol; 2013 May; 113(1):127-34. PubMed ID: 23459995
[TBL] [Abstract][Full Text] [Related]
3. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.
Aguilera D; Mazewski C; Fangusaro J; MacDonald TJ; McNall-Knapp RY; Hayes LL; Kim S; Castellino RC
Childs Nerv Syst; 2013 Apr; 29(4):589-96. PubMed ID: 23296323
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
5. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.
Modak S; Kushner BH; Basu E; Roberts SS; Cheung NK
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28111925
[TBL] [Abstract][Full Text] [Related]
6. Dramatic response to temozolomide, irinotecan, and bevacizumab for recurrent medulloblastoma with widespread osseous metastases.
Bonney PA; Santucci JA; Maurer AJ; Sughrue ME; McNall-Knapp RY; Battiste JD
J Clin Neurosci; 2016 Apr; 26():161-3. PubMed ID: 26777082
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.
Le Teuff G; Castaneda-Heredia A; Dufour C; Jaspan T; Calmon R; Devos A; McHugh K; Leblond P; Frappaz D; Aerts I; Zwaan CM; Ducassou S; Chastagner P; Verschuur A; Corradini N; Casanova M; Rubie H; Riccardi R; Le Deley MC; Vassal G; Geoerger B;
Pediatr Blood Cancer; 2020 Jan; 67(1):e28032. PubMed ID: 31595663
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.
Bagatell R; London WB; Wagner LM; Voss SD; Stewart CF; Maris JM; Kretschmar C; Cohn SL
J Clin Oncol; 2011 Jan; 29(2):208-13. PubMed ID: 21115869
[TBL] [Abstract][Full Text] [Related]
9. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
Wagner LM; Crews KR; Iacono LC; Houghton PJ; Fuller CE; McCarville MB; Goldsby RE; Albritton K; Stewart CF; Santana VM
Clin Cancer Res; 2004 Feb; 10(3):840-8. PubMed ID: 14871959
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
Bagatell R; Norris R; Ingle AM; Ahern C; Voss S; Fox E; Little AR; Weigel BJ; Adamson PC; Blaney S
Pediatr Blood Cancer; 2014 May; 61(5):833-9. PubMed ID: 24249672
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.
Cefalo G; Massimino M; Ruggiero A; Barone G; Ridola V; Spreafico F; Potepan P; Abate ME; Mascarin M; Garrè ML; Perilongo G; Madon E; Colosimo C; Riccardi R
Neuro Oncol; 2014 May; 16(5):748-53. PubMed ID: 24482446
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma.
Gruber ML; Buster WP
Am J Clin Oncol; 2004 Feb; 27(1):33-8. PubMed ID: 14758131
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients.
Palmerini E; Jones RL; Setola E; Picci P; Marchesi E; Luksch R; Grignani G; Cesari M; Longhi A; Abate ME; Paioli A; Szucs Z; D'ambrosio L; Scotlandi K; Fagioli F; Asaftei S; Ferrari S
Acta Oncol; 2018 Jul; 57(7):958-964. PubMed ID: 29533113
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors.
Venkatramani R; Malogolowkin M; Davidson TB; May W; Sposto R; Mascarenhas L
PLoS One; 2013; 8(7):e68416. PubMed ID: 23894304
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients.
Kim H; Kang HJ; Lee JW; Park JD; Park KD; Shin HY; Ahn HS
Childs Nerv Syst; 2013 Oct; 29(10):1851-8. PubMed ID: 23748464
[TBL] [Abstract][Full Text] [Related]
17. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
Jones SF; Gian VG; Greco FA; Miranda FT; Shipley DL; Thompson DS; Hainsworth JD; Toomey MA; Willcutt NT; Burris HA
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):41-5. PubMed ID: 12800606
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
Wagner LM; Perentesis JP; Reid JM; Ames MM; Safgren SL; Nelson MD; Ingle AM; Blaney SM; Adamson PC
Pediatr Blood Cancer; 2010 Apr; 54(4):538-45. PubMed ID: 20049936
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.
Wagner LM; McAllister N; Goldsby RE; Rausen AR; McNall-Knapp RY; McCarville MB; Albritton K
Pediatr Blood Cancer; 2007 Feb; 48(2):132-9. PubMed ID: 16317751
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.
Casey DA; Wexler LH; Merchant MS; Chou AJ; Merola PR; Price AP; Meyers PA
Pediatr Blood Cancer; 2009 Dec; 53(6):1029-34. PubMed ID: 19637327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
